HOOKIPA Pharma Inc. (HOOK)

NASDAQ: HOOK · IEX Real-Time Price · USD
0.625
+0.031 (5.31%)
At close: Sep 27, 2023, 4:00 PM
0.634
+0.009 (1.50%)
After-hours: Sep 27, 2023, 7:28 PM EDT
5.31%
Market Cap 52.51M
Revenue (ttm) 15.91M
Net Income (ttm) -68.29M
Shares Out 84.01M
EPS (ttm) -0.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,796,646
Open 0.600
Previous Close 0.594
Day's Range 0.550 - 0.640
52-Week Range 0.550 - 2.050
Beta 0.68
Analysts Buy
Price Target 4.05 (+548.0%)
Earnings Date Nov 13, 2023

About HOOK

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cance... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 18, 2019
Employees 156
Stock Exchange NASDAQ
Ticker Symbol HOOK
Full Company Profile

Financial Performance

In 2022, HOOKIPA Pharma's revenue was $14.25 million, a decrease of -22.76% compared to the previous year's $18.45 million. Losses were -$64.92 million, -14.21% less than in 2021.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for HOOK stock is "Buy." The 12-month stock price forecast is $4.05, which is an increase of 548.00% from the latest price.

Price Target
$4.05
(548.00% upside)
Analyst Consensus: Buy
Stock Forecasts

News

HOOKIPA Announces Executive Leadership Change

NEW YORK and VIENNA, Sept. 13, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platfo...

14 days ago - GlobeNewsWire

HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and VIENNA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platfo...

15 days ago - GlobeNewsWire

HOOKIPA Pharma to participate in upcoming investor conferences in September

NEW YORK and VIENNA, Austria, Sept. 06, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavir...

21 days ago - GlobeNewsWire

HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

NEW YORK and VIENNA, Austria, Aug. 10, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenaviru...

6 weeks ago - GlobeNewsWire

HOOKIPA Pharma to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 10, 2023

NEW YORK and VIENNA, Austria, Aug. 03, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenaviru...

7 weeks ago - GlobeNewsWire

HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and VIENNA, Austria, June 10, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenaviru...

3 months ago - GlobeNewsWire

HOOKIPA Pharma Announces Pricing of $50.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred Stock

NEW YORK and VIENNA, Austria, May 31, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (Nasdaq: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus...

4 months ago - GlobeNewsWire

HOOKIPA Pharma Announces Positive Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab in Patients with HPV16+ Head and Neck Cancers

NEW YORK and VIENNA, Austria, May 31, 2023 (GLOBE NEWSWIRE) --  HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenaviru...

4 months ago - GlobeNewsWire

HOOKIPA Pharma Reports First Quarter 2023 Financial Results and Recent Business Highlights

NEW YORK and VIENNA, May 11, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform...

4 months ago - GlobeNewsWire

HOOKIPA Announces First Person Dosed in Phase 1a/b Clinical Trial of HB-400, in Collaboration with Gilead, for Treatment of Hepatitis B

NEW YORK and VIENNA, Austria, May 09, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus...

5 months ago - GlobeNewsWire

HOOKIPA Pharma to Participate in Upcoming Investor Conferences in May

NEW YORK and VIENNA, Austria, May 04, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus...

5 months ago - GlobeNewsWire

HOOKIPA Pharma to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 11, 2023

NEW YORK and VIENNA, Austria, May 04, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus...

5 months ago - GlobeNewsWire

HOOKIPA to Present a Trial in Progress Poster on its Prostate Cancer Phase 1/2 Clinical Trial at ASCO

NEW YORK and VIENNA, Austria, April 26, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavir...

5 months ago - GlobeNewsWire

HOOKIPA Pharma to Participate in the Van Lanschot Kempen Life Sciences Conference

NEW YORK and VIENNA, Austria, April 19, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavir...

5 months ago - GlobeNewsWire

HOOKIPA Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook

NEW YORK and VIENNA, March 15, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platfo...

7 months ago - GlobeNewsWire

HOOKIPA Pharma Appoints Terry Coelho to its Board of Directors

NEW YORK and VIENNA, March 13, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platfo...

7 months ago - GlobeNewsWire

HOOKIPA Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 15, 2023

NEW YORK and VIENNA, March 08, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platfo...

7 months ago - GlobeNewsWire

HOOKIPA Achieves $10 Million Milestone Payment in Development of Immunotherapy for KRAS-Mutated Cancers

NEW YORK and VIENNA, Austria, Feb. 13, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapies based on its proprietary arenavirus p...

8 months ago - GlobeNewsWire

HOOKIPA to Present at the SVB Securities Global Biopharma Conference

NEW YORK and VIENNA, Austria, Feb. 07, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenaviru...

8 months ago - GlobeNewsWire

HOOKIPA Pharma Achieves $5 Million Milestone Payment from Gilead Sciences for Progress in the Development of Hepatitis B Vaccine

NEW YORK and VIENNA, Austria, Jan. 04, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapies based on its proprietary arenavirus p...

9 months ago - GlobeNewsWire

HOOKIPA Pharma Appoints Katia Schlienger, M.D., Ph.D., Chief Medical Officer and Malte Peters, M.D.

NEW YORK and VIENNA, Austria, Dec. 15, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenaviru...

10 months ago - GlobeNewsWire

HOOKIPA to Participate in The JMP Securities Hematology and Oncology Summit

NEW YORK and VIENNA, Austria, Nov. 30, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenaviru...

10 months ago - GlobeNewsWire

HOOKIPA Pharma Announces Third Quarter 2022 Financial Results and Provides a Business Update

NEW YORK and VIENNA, Austria, Nov. 14, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapies based on its proprietary arenavirus p...

11 months ago - GlobeNewsWire

HOOKIPA Pharma to Report Third Quarter 2022 Financial Results and Corporate Updates on November 14, 2022

NEW YORK and VIENNA, Austria, Nov. 07, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapies based on its proprietary arenavirus p...

11 months ago - GlobeNewsWire

HOOKIPA to Participate in the Sidoti Micro-Cap Virtual Conference

NEW YORK and VIENNA, Austria, Nov. 02, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenaviru...

11 months ago - GlobeNewsWire